Urethral hypermobility

From WikiProjectMed
Jump to navigation Jump to search

Urethral hypermobility is a condition of excessive movement of the female urethra due to a weakened urogenital diaphragm. It describes the instability of the urethra in relation to the pelvic floor muscles. A weakened pelvic floor muscle fails to adequately close the urethra and hence can cause stress urinary incontinence. This condition may be diagnosed by primary care providers or urologists. Treatment may include pelvic floor muscle exercises, surgery (e.g. urethral sling), or minimally invasive procedures (e.g. urethral bulking injections).[1][2]

Anatomy

Scientific illustrations of pelvic floor muscles showing urethra and nearby muscles in both males and females
Muscles of the pelvic floor in males and females and location of urethra.

The urethra is held in place in relationship to the pelvic bones and bladder by a combination of ligaments, pelvic floor muscles, and surrounding connective tissue known as the urogenital diaphragm. Damage to any of these structures, or the nerves that control them can cause the urethra to be displaced from its normal position or to have increased range of motion. This can result in lack of effective closure of the urethra and thus urinary leakage, especially when pressure from the abdomen is increased during physical exertion and cough, sneeze, or valsalva maneuvers.[3]

Illustration showing cross section of male and female pelvis with labels showing bladder and urethra and other pelvic structures like the rectum, uterus, and vagina.
Pelvic organs including bladder and urethra in both males and females.

Female anatomical considerations

Changes during pregnancy and physical trauma during childbirth can cause damage to the pubosacral ligament, uterosacral ligament, and pelvic floor muscles, and the connection of the pubic bone itself. Any of these changes may contribute to urethral hypermobility.[1]

Male anatomical considerations

Males have a lower incidence of urethral hypermobility than females, but prostatectomy is one risk factor urethral hypermobility and stress incontinence.[4]

Diagnosis

Urethral hypermobility is often diagnosed indirectly by achieving a diagnosis of stress urinary incontinence. This could include ruling out other types of incontinence and other abnormalities, and specific tests for stress incontinence, for example testing for urinary leakage during cough. Specialized testing to further characterize the degree of urethral hypermobility may include urodynamic testing, voiding cystourethrography, pelvic ultrasound, and electromyography.[5] These modalities are only recommended for people who experience ongoing symptoms despite an adequate trial of pelvic floor muscle training.[6]

Treatment

Pelvic Floor Muscle Training

The first line treatment for urethral hypermobility is pelvic floor exercises under supervision of a physical therapist. However, there is no consensus on which training regiments are most effective, and studies have not determined which mechanisms improve the function of the pelvic floor muscles (e.g. improving reflex action of muscles in response to abdominal pressure vs. increasing urethral closing pressure).[1][7]

Weight Loss

Loss of 5-10% of weight has been shown to result in mild improvement in symptoms that was persistent across follow-up periods of 1-3 years.[1]

Medication

Duloxetine is a medication in the Serotonin–norepinephrine reuptake inhibitor class which is approved in Europe for treatment of stress urinary incontinence and used off-label in America for the treatment of stress urinary incontinence.[1]

Surgery

Several surgical procedures are available to treat urethral hypermobility. These procedures use combinations of sutures, implanted synthetic mesh, and autotransplanted tissue to support and reposition the urethra in relation to the pubic bone and other pelvic structures.

Surgical meshes have come to the public attention due to safety concerns with vaginal mesh used to treat pelvic organ prolapse, however, the urethral sling surgeries have been demonstrated to be highly effective with low risk of adverse events.[1]

Other procedures

Urethral bulking involves injecting an inert material into the wall of the urethra to relieve the symptoms of urethral hypermobility. This technique is less invasive than surgery with lower risk of adverse events, however it has a lower cure rate for stress incontinence than other methods.[1]

Lifestyle Interventions

Lifestyle interventions such as limiting water intake and scheduling urination are not proven to be effective.[1]

Research areas

Stem-cell therapy and Electrical muscle stimulation are being explored to assist regeneration of damaged tissue and muscle growth in the urogenital diaphragm. These trials have been explored in animals in vivo and In vitro studies, but have not yet been explored in humans.[8]


Reference

  1. ^ a b c d e f g h Wu JM (June 2021). Solomon CG (ed.). "Stress Incontinence in Women". The New England Journal of Medicine. 384 (25): 2428–2436. doi:10.1056/NEJMcp1914037. PMID 34161707. S2CID 235625388.
  2. ^ Cho ST, Kim KH (December 2021). "Pelvic floor muscle exercise and training for coping with urinary incontinence". Journal of Exercise Rehabilitation. 17 (6): 379–387. doi:10.12965/jer.2142666.333. PMC 8743604. PMID 35036386.
  3. ^ Quaghebeur J, Petros P, Wyndaele JJ, De Wachter S (October 2021). "Pelvic-floor function, dysfunction, and treatment". European Journal of Obstetrics, Gynecology, and Reproductive Biology. 265: 143–149. doi:10.1016/j.ejogrb.2021.08.026. hdl:10067/1824640151162165141. PMID 34492609.
  4. ^ Canning A, Raison N, Aydin A, Cheikh Youssef S, Khan S, Dasgupta P, Ahmed K (November 2022). "A systematic review of treatment options for post-prostatectomy incontinence". World Journal of Urology. 40 (11): 2617–2626. doi:10.1007/s00345-022-04146-5. PMC 9617828. PMID 36107210.
  5. ^ Falah-Hassani K, Reeves J, Shiri R, Hickling D, McLean L (March 2021). "The pathophysiology of stress urinary incontinence: a systematic review and meta-analysis". International Urogynecology Journal. 32 (3): 501–552. doi:10.1007/s00192-020-04622-9. PMC 8053188. PMID 33416968.
  6. ^ Hu JS, Pierre EF (September 2019). "Urinary Incontinence in Women: Evaluation and Management". American Family Physician. 100 (6): 339–348. PMID 31524367.
  7. ^ Sheng Y, Carpenter JS, Ashton-Miller JA, Miller JM (May 2022). "Mechanisms of pelvic floor muscle training for managing urinary incontinence in women: a scoping review". BMC Women's Health. 22 (1): 161. doi:10.1186/s12905-022-01742-w. PMC 9103460. PMID 35562699.
  8. ^ Harland N, Walz S, Eberli D, Schmid FA, Aicher WK, Stenzl A, Amend B (September 2023). "Stress Urinary Incontinence: An Unsolved Clinical Challenge". Biomedicines. 11 (9): 2486. doi:10.3390/biomedicines11092486. PMC 10525672. PMID 37760927.